Loading
A phase 2 trial of ivonescimab in lung cancer, run by Shaodong Hong, not yet recruiting.
Paclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLC is a phase 2, interventional study registered as NCT07819591 by Shaodong Hong, with a registry enrolment figure of 47 participants, started 2026-10-01 and due to reach its primary completion in 2028-12-01. Interventions recorded: Paclitaxel Polymeric Micelles; Ivonescimab. Conditions listed: SCLC, Recurrent. Primary outcome: Outcome Objective Response Rate (ORR) assessed by RECIST v1.1. Lung eligibility wording from the registry: "* Histologically or cytologically confirmed relapsed small-cell lung cancer after failure of platinum-based chemotherapy and PD-1/PD-L1 monoclonal antibody treatment". Sites: China. No results are recorded here; the registry entry is the source.
Shares Ivonescimab, Bispecific antibodies, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Ivonescimab, Bispecific antibodies, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Ivonescimab, Bispecific antibodies, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Ivonescimab, Bispecific antibodies, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Ivonescimab, Bispecific antibodies, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Ivonescimab, Bispecific antibodies, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Ivonescimab, Bispecific antibodies, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Ivonescimab, Bispecific antibodies, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.